Pleiotropic effects of heparin and heparinoids in peritoneal dialysis

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 1, 2009, Pages 92-97

  Gozdzikiewicz, Joanna ^a   Borawski, Jacek ^a,b   Mysliwiec, Michal ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b NONE   (Poland)

Author keywords

Glycosaminoglycans; Heparin; Peritoneal dialysis; Sulodexide

Indexed keywords

DALTEPARIN; ENOXAPARIN; GROWTH FACTOR; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; SULODEXIDE; TINZAPARIN;

CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; FIBROSIS; HOMEOSTASIS; HUMAN; INFLAMMATION; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PERITONEAL SCLEROSIS; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; SCLEROSIS; VASCULAR DISEASE;

ANIMALS; ANTICOAGULANTS; GLYCOSAMINOGLYCANS; HEPARIN; HUMANS; PERITONEAL DIALYSIS; PERITONEUM; RETROSPECTIVE STUDIES;

EID: 58449135502     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607304722     Document Type: Review

References (48)

1. Goel S., Misra M., Saran R., Khanna R. The rationale for, and role of, heparin in peritoneal dialysis. Adv Perit Dial. 1998 ; 14: 111-115.
2. Tyrell DJ, Kilfeather S., Page CP Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci. 1995 ; 16: 198-204.
3. Taylor KR, Gallo RL Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation of inflammation. FASEB J. 2006 ; 20: 9-22.
4. Wang L., Brown JR, Varki A., Esko JD Heparin's antiinflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest. 2002 ; 110: 127-136.
5. Hochart H., Jenkins PV, Smith OP, White B. Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-κB in LPS-stimulated human monocytes. Br J Haematol. 2006 ; 133: 62-67.
6. Smorenburg SM, van Noorden CJF. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev. 2001 ; 53: 93-105.
7. Li W., Zhang J., Huang Q., Zhu H., Zhang X. Long-term administering low anticoagulant activity heparin can lessen rat hepatic fibrosis induced by either CCl(4) or porcine serum injection. Hepatol Res. 2006 ; 36: 115-123.
8. Gunther A., Lubke N., Ermert M., et al. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med. 2003 ; 168: 1358-1365.
9. Pecly IM, Goncalves RG, Rangel EP, et al. Effects of low molecular weight heparin in obstructed kidneys: decrease of collagen, fibronectin and TGF-κ, and increase of chondroitin/dermatan sulphate proteoglycans and macrophage infiltration. Nephrol Dial Transplant. 2006 ; 21: 1212-1222.
10. Shi J., Hao JH, Ren WH, Zhu JR Effects of heparin on liver fibrosis in patients with chronic hepatitis B. World J Gastroenterol. 2003 ; 9: 1611-1614.
11. Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS 2006 ; 114: 79-102.
12. Coles GA, Williams JD What is the place of peritoneal dialysis in the integrated treatment of renal failure ? Kidney Int. 1998 ; 54: 2234-2240.
13. Mortier S., Faict D., Lameire NH, De Vriese AS Benefits of switching from conventional to a low-GDP bicarbonate/ lactate-buffered dialysis solution in a rat model. Kidney Int. 2005 ; 4: 1559-1565.
14. Bajo MA, del Peso G., Castro MA, et al. Effect of bicarbonate/lactate peritoneal dialysis solutions on human mesothelial cell proliferation ex vivo. Adv Perit Dial. 2001 ; 17: 37-41.
15. Schwenger V., Morath C., Salava A., et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol. 2006 ; 17: 199-207.
16. De Vriese AS, Flyvbjerg A., Mortier S., Tilton RG, Lameire NH Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol. 2003 ; 14: 2109-2118.
17. Do JY, Kim YL, Park JW, et al. The effect of low glucose degradation product dialysis solutions on epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 2005 ; 25 (suppl 3). S22 - S25.
18. Lai KN, Lai KB, Lam CW, Chan TM, Li FK, Leung JC Changes in cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 2000 ; 4: 644-652.
19. Tsai TJ, Yen CJ, Fang CC, Yang CC, Lee PH, Yen TS Effect of intraperitoneally administered agents on human peritoneal mesothelial cell growth. Nephron. 1995: 71: 23-28.
20. Williams JD, Craig KJ, von Ruhland C., Topley N., Williams GT, Biopsy Registry Study Group. The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int Suppl. 2003 ; 88: S43 - S49.
21. Mateijsen M., van der Wal A., Hendriks P., et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int. 1999 ; 19: 517-525.
22. Struijk DG, Krediet RT, Koomen GC, et al. Functional characteristics of the peritoneal membrane in long-term continuous ambulatory peritoneal dialysis. Nephron. 1991 ; 59: 213-220.
23. Struijk DG, Krediet RT, Koomen GCM, Boeschoten, EW, Hoek FJ, Arisz S. A prospective study of peritoneal transport in CAPD patients. Kidney Int. 1994 ; 45: 1739-1744.
24. Bazzato G., Fracasso A., Gambaro G., Baggio B. Use of glycosaminoglycans to increase efficiency of long-term continuous peritoneal dialysis. Lancet. 1995 ; 346: 740-741.
25. Fracasso A., Baggio B., Ossi E., et al. Glycosaminoglycans prevent the functional and morphological peritoneal derangement in an experimental model of peritoneal fibrosis. Am J Kidney Dis. 1999 ; 33: 105-110.
26. Fracasso A., Baggio B., Masiero M., et al. Effect of oral treatment with the glycosaminoglycan sulodexide on peritoneal transport in CAPD patients. Perit Dial Int. 2003 ; 23: 595-599.
27. Bazargani F., Albrektsson A., Yahyapour N., Braide M. Low molecular weight heparin improves peritoneal ultrafiltration and blocks complement and coagulation. Perit Dial Int. 2005 ; 25: 394-404.
28. Pawlaczyk K., Kuzlan-Pawlaczyk M., Anderstam B., et al. Effects of intraperitoneal heparin on peritoneal transport in a chronic model of peritoneal dialysis. Nephrol Dial Transplant. 2001 ; 16: 669-671.
29. De Vriese AS, Mortier S., Cornelissen M., et al. The effects of heparin administration in animal model of chronic peritoneal dialysate exposure. Perit Dial Int. 2002 ; 22: 566-572.
30. Sjøland JA, Pedersen RS, Jespersen J., Gram J. Intraperitoneal heparin reduces peritoneal permeability and increases ultrafiltration in peritoneal dialysis patients. Nephrol Dial Transplant. 2004 ; 19: 1264-1268.
31. Sjøland JA, Pedersen RS, Jespersen J., Gram J. Intraperitoneal heparin ameliorates the systemic inflammatory response in PD patients. Nephron Clin Pract 2005 ; 100: c105 - c110.
32. Sifil A., Mermut C., Yenicerioglu Y., et al. Intraperitoneal and subcutaneous pharmacokinetics of low molecular weight heparin in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial. 2003 ; 19: 28-30.
33. Oh KH, Margetts PJ Cytokines and growth factors involved in peritoneal fibrosis of peritoneal dialysis patients. Int J Artif Organs. 2005 ; 28: 129-134.
34. Myint KM, Yamamoto Y., Doi T., et al. RAGE control of diabetic nephropathy in a mouse model. Effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes. 2006 ; 55: 2510-2522.
35. Margetts PJ, Bonniaud P., Liu L., et al. Transient overexpression of TGF-κ1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol. 2005 ; 16: 425-436.
36. Medcalf JF, Walls J., Pawluczyk IZ, Harris KP Effects of glucose dialysate on extracellular matrix production by human peritoneal mesothelial cells (HPMC): the role of TGF-κ. Nephrol Dial Transplant. 2001 ; 16: 1885-1892.
37. Weigert C., Brodbeck K., Häring HU, Gambaro G., Schleicher ED Low-molecular-weight heparin prevents high glucose- and phorbol ester-induced TGF-κ1 gene activation. Kidney Int. 2001 ; 60: 935-943.
38. Matsuo K., Maeda Y., Naiki Y.,, et al. Possible effects of hepatocyte growth factor for prevention of peritoneal fibrosis. Nephron Exp Nephrol. 2005 ; 99: e87 - e94.
39. Nakamura S., Niwa T. Pyridoxal phosphate and hepatocyte growth factor prevent dialysate-induced peritoneal damage. J Am Soc Nephrol. 2005 ; 16: 144-150.
40. Liu Y., Rajur K., Tolbert E., Dworkin LD Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. Kidney Int. 2000 ; 58: 2028-2043.
41. Dai C., Liu Y. Hepatocyte growth factor antagonizes the profibrotic action of TGF-κ1 in mesangial cells by stabilizing Smad transcriptional corepressor TGIF. J Am Soc Nephrol. 2004 ; 15: 1402-1412.
42. Mizuno S., Nakamura T. Suppression of chronic glomerular injuries and TGF-κ1 production by HGF in attenuation of murine diabetic nephropathy. Am J Physiol Renal Physiol. 2004 ; 286: F134 - F143.
43. Dai C., Yang J., Bastacky S., Xia J., Li Y., Liu Y. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. J Am Soc Nephrol. 2004 ; 15: 2637-2647.
44. Seidel C., Hjorth-Hansen H., Bendz B., et al. Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals. Br J Haematol. 1999 ; 105: 641-647.
45. Salbach PB, Bruckmann M., Turovets O., Kreuzer J., Kubler W., Walter-Sack I. Heparin-mediated selective release of hepatocyte growth factor in humans. Br J Clin Pharmacol. 2000 ; 50: 221-226.
46. Borawski J., Naumnik B., Mysliwiec M. Striking increase in circulating hepatocyte growth factor during enoxaparinanticoagulated haemodialysis. Nephrol Dial Transplant. 2003 ; 18: 1680-1682.
47. Borawski J., Naumnik B., Mysliwiec M. Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: role of heparin. Kidney Int. 2003 ; 64: 2229-2237.
48. Borawski J., Dubowski M., Pawlak K., Mysliwiec M. Sulodexide induces hepatocyte growth factor release in humans. Eur J Pharmacol. 2007 ; 558: 167-171.